Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of 5-ALA-HCl/SFC in corticosteroid-refractory adult-onset Still's disease
jRCT2071220040Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 5-aminolevulinic acid and sodium ferrous citrate in adult-onset Still's disease (AOSD) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Adapted ACR 30 response at week 4. Started Dec 2022; status: completed.
02
Drugs
5-aminolevulinic acidsodium ferrous citrate
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on jRCT2071220040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220040.